Lilly’s AtaiBeckley buy validates space as Big Pharma takes note of psychedelics
BioSpace
Eli Lilly's proposed acquisition of AtaiBeckley is "the clearest strategic validation to date" of psychedelics as an emerging pharmaceutical category, according to H.C.
pharminent
July 20, 2026 (Last updated: July 21, 2026)
BioSpace
Eli Lilly’s proposed acquisition of AtaiBeckley is “the clearest strategic validation to date” of psychedelics as an emerging pharmaceutical category, according to H.C.